News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson has delivered a 68.9% total return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) intrinsic value …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …
Quick Read PEY requires 10 straight years of dividend growth before yield ranking, and it delivered roughly 25% in 2026, which is nearly double the S&P 500's gain. Altria has raised its dividend 60 consecutive times over 56 years, while Johnson & Johnson just …
Quick Read JNJ sits 1% below its 52-week high after a 55% one-year run, with analyst consensus targets just 4% above current price. DARZALEX cleared $4 billion in Q2 and TREMFYA grew 71%, but STELARA's 60% collapse strips roughly 920 basis points from Innovative …
In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to …
Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The …
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …
Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that's the part of the J&J story that rarely gets enough attention. When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you …
Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …
Agreement supports ACCESS-affiliated ASCs in adopting the CARTO™ System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio …
Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow …
Key Points Johnson & Johnson has historically been a safe haven during turbulent times. Coca-Cola, like J&J, is a Dividend King with a record of resilience. Chevron is an energy giant with a huge AI tailwind.10 stocks we like better than Johnson & Johnson …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced …
Photo by Rigby40 on Pixabay The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them. Over the last five years, Johnson & Johnson (JNJ) sent $85 …
NEW BRUNSWICK, N.J., August 04, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of …
Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money's July 23 episode. After days of urging investors to accumulate the stock following a strong earnings report that Wall Street initially dismissed, Cramer highlighted the FDA approval …
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …
Helus Pharma Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and commercialization Appointed as Helus …
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for? View Comments
Collecting regular dividends is great for passive income or for unleashing the power of compounding through dividend reinvestment. That is, until a corporation decides to suspend its dividend program altogether. Fortunately, investors don't have to deal with that problem or, at least, can reduce …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked …
Choosing between Abbott Laboratories (NYSE:ABT) and Johnson & Johnson (NYSE:JNJ) involves weighing steady growth against massive scale. Both healthcare giants offer stability, but which represents the superior investment for you in 2026? Abbott focuses on high-tech diagnostics and life-saving medical devices, while Johnson & …
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …
This story was originally published on Supply Chain Dive. To receive daily news and insights, subscribe to our free daily Supply Chain Dive newsletter. Johnson & Johnson is undergoing a restructuring of its supply chain, primarily in its innovative medicine segment, according to a …
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving …
(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced a strategic collaboration with Sail Biomedicines to develop in-vivo CAR-T cell therapies for immune-mediated diseases. The collaboration will leverage Sail's AI-driven Endless RNA (eRNA) platform and targeted nanoparticle platform along with other leading product engines, …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long …
Combines Sail's patented eRNA™ and targeted nanoparticle modality with Johnson & Johnson's world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-mediated diseases Sail to receive initial payments of $785 million from Johnson & Johnson1, including …
Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances leadership in next-generation antibody engineering to accelerate oncology innovation NEW BRUNSWICK, N.J., July 29, 2026--(BUSINESS WIRE)--Johnson & Johnson …
Search by ticker symbol or company name and select a result to open its chart.